Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat

Rajash Handa, Jack W. Strandhoy, Vardaman M. Buckalew

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5 - 25 ng/kg) and C18-PAF (2.5 - 200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6 - 15%) before causing dose-dependant systemic hypotension (2 - 64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-PAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25 - 200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.

Original languageEnglish (US)
Pages (from-to)747-752
Number of pages6
JournalLife Sciences
Volume49
Issue number10
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Renal Circulation
Blood pressure
Vasodilator Agents
Rats
Blood
Blood Pressure
Kidney
Injections
Enantiomers
Platelet Activating Factor
Hypotension
Wistar Rats
Lipids
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat. / Handa, Rajash; Strandhoy, Jack W.; Buckalew, Vardaman M.

In: Life Sciences, Vol. 49, No. 10, 1991, p. 747-752.

Research output: Contribution to journalArticle

@article{22527ffdca5643c3b0ba2de48a247e99,
title = "Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat",
abstract = "The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5 - 25 ng/kg) and C18-PAF (2.5 - 200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6 - 15{\%}) before causing dose-dependant systemic hypotension (2 - 64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-PAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25 - 200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.",
author = "Rajash Handa and Strandhoy, {Jack W.} and Buckalew, {Vardaman M.}",
year = "1991",
doi = "10.1016/0024-3205(91)90107-M",
language = "English (US)",
volume = "49",
pages = "747--752",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Vasorelaxant effect of C16-PAF and C18-PAF on renal blood flow and systemic blood pressure in the anesthetized rat

AU - Handa, Rajash

AU - Strandhoy, Jack W.

AU - Buckalew, Vardaman M.

PY - 1991

Y1 - 1991

N2 - The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5 - 25 ng/kg) and C18-PAF (2.5 - 200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6 - 15%) before causing dose-dependant systemic hypotension (2 - 64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-PAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25 - 200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.

AB - The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5 - 25 ng/kg) and C18-PAF (2.5 - 200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6 - 15%) before causing dose-dependant systemic hypotension (2 - 64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-PAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25 - 200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.

UR - http://www.scopus.com/inward/record.url?scp=0025923568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025923568&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(91)90107-M

DO - 10.1016/0024-3205(91)90107-M

M3 - Article

VL - 49

SP - 747

EP - 752

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 10

ER -